유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - majjali - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - inactivated rabbit haemorrhagic disease type 2 virus (rhdv2), strainv-1037 - vaċċini virali inattivati - fniek - għall-immunizzazzjoni attiva tal-fniek mill-età ta ' 30 ġurnata biex titnaqqas il-mortalità kkawżata mill-marda emorraġika tal-fniek it-tip 2 virus (rhdv2).

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - erysipelothrix rhusiopathiae, strain r32e11 (mhux attivat) - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - majjali - għall-immunizzazzjoni attiva ta 'l-irġiel u tan-nisa, l-majjali biex tnaqqas is-sinjali kliniċi (leżjonijiet tal-ġilda u deni) ta' erysipelas majjali kkawżata minn erysipelothrix rhusiopathiae, serotip 1 u serotip 2.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - parvovirus tal-ħnieżer, strain nadl-2 u erysipelothrix rhusiopathiae, strain r32e11 (inattivat) - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - majjali - għall-immunizzazzjoni attiva ta 'majjali femminili għall-protezzjoni tal-proġenija kontra infezzjoni transplacental ikkawżata minn parvovirus tal-ħnieżer. għall-immunizzazzjoni attiva ta 'l-irġiel u tan-nisa, l-majjali biex tnaqqas is-sinjali kliniċi (leżjonijiet tal-ġilda u deni) ta' erysipelas majjali kkawżata minn erysipelothrix rhusiopathiae, serotip 1 u serotip 2.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra s.a - virus ħaj tal-virus tal-herpes tal-ifrat imħallat b'ġenet doppju tip 1, razza ceddel: 106.3-107.3 ccid50 - immunoloġiċi - bhejjem - għal-immunizzazzjoni attiva tal-bhejjem mill-età ta 'tliet xhur kontra l-bovini virus herpes tat-tip 1 (bohv-1) biex jitnaqqsu s-sinjali kliniċi ta' infectious bovine rhinotracheitis (ibr) u l-eskrezzjoni tal-virus fil-qasam. il-bidu tal-immunità: 21 jum wara t-tlestija tal-iskema bażika tat-tilqim. tul ta 'żmien tal-immunità: 6 xhur wara t-tkomplija tal-iskema bażika tat-tilqim.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - eimeria acervulina, razza 003, eimeria maxima, razza 013, eimeria mitis, razza 006, eimeria praecox, razza 007, eimeria tenella, razza 004 - parassiti ħajjin, il-vaċċini immunoloġiċi għall-aves - chicken - għal-immunizzazzjoni attiva tal-flieles mill-1 ta'kuljum ta'l-età biex jitnaqqas intestinali leżjonijiet u oocysts-produzzjoni assoċjati mal-koċċidjożi kkawżata mill-eimeria acervulina, eimeria maxima, eimeria mitis, eimeria praecox u l-eimeria tenella u biex tnaqqas sinjali kliniċi (dijarea) assoċjata mal-eimeria acervulina, eimeria-limiti massimi u eimeria tenella.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios syva, s.a.u. - inattivat tal-virus tal-bluetongue serotip 1, tar-razza alg2006/01 e1, inattivat tal-virus tal-bluetongue serotip 4, razza btv-4/spa-1/2004, inattivat tal-virus tal-bluetongue serotip 8, razza bel2006/01 - vaċċini virali inattivati - cattle; sheep - għall-immunizzazzjoni attiva ta ' nagħaġ għall-prevenzjoni kontra viremja u tnaqqas sinjali kliniċi u leżjonijiet ikkawżati mill-virus tal-bluetongue-serotipi tat-1 u/jew 8 u/jew inaqqas viremja*, u sinjali kliniċi u leżjonijiet ikkawżati mill-virus tal-bluetongue tas-serotip 4for-immunizzazzjoni attiva tal-bovini għall-prevenzjoni kontra viremja ikkawżat mill-virus tal-bluetongue-serotipi tat-1 u/jew 8 u/jew inaqqas viremja* ikkawżat mill-virus tal-bluetongue tas-serotip 4.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra s.a. - virus ħaj inattivat tal-respiratorja bovina-virus sinktjali (brsv), razza lym-56 - immunoloġiċi għall-bovini, baqar, vaċċini virali Ħajjin, respiratorja bovina-virus sinktjali (brsv) - bhejjem - tilqim attiv ta ' baqar biex jitnaqqsu l-virus jixħtu u respiratorji is-sinjali kliniċi ikkawżati mill-respiratorja bovina-infezzjoni tal-virus sinktjali.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - majjali - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

abbott laboratories ltd. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; arthritis, psoriatic; crohn disease - immunosoppressanti - rewmatika arthritistrudexa flimkien ma ' methotrexate, huwa indikat għall -: - trattament ta moderata sa severa, artrite rewmatika attiva f'pazjenti adulti, meta r-rispons li jimmodifikaw il-marda anti-rewmatiċi-mediċini inkluż methotrexate, ma jkunx adegwat. il-kura ta attiva u progressiva severa, artrite rewmatika fl-adulti li ma kienux ittrattati qabel b'methotrexate. trudexa jista 'jingħata waħdu f'każ ta' intolleranza għal methotrexate jew meta trattamenti fit-tul b'methotrexate mhux adattat. intwera li trudexa jnaqqas ir-rata ta 'progressjoni tal-ħsara fil-ġogi kif imkejjel permezz ta' x-ray, u li jtejjeb il-funzjoni fiżika, meta jingħata flimkien ma ' methotrexate. psorjatika arthritistrudexa huwa indikat għall-kura tas-sustanza attiva u progressiva artrite psorjatika fl-adulti meta r-rispons għall-preċedenti li jimmodifikaw il-marda anti-rewmatiċi terapija bil-mediċina kienet inadegwata. ankylosing spondylitistrudexa huwa indikat għall-kura ta ' adulti li jbatu minn ankylosing spondylitis attiva li kellhom rispons mhux adekwat għat-terapija. crohn diseasetrudexa huwa indikat għall-kura ta ' marda ta'crohn attiva, f'pazjenti li ma kellhomx rispons minkejja sħiħ u adegwat matul it-terapija b'xi corticosteroid u/jew immunosoppressanti; jew li huma intolleranti għal, jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn. għall-kura tal-bidu, trudexa għandu jingħata flimkien ma ' corticosteroids. trudexa jista 'jingħata bħala monoterapija f'kaz ta' intolleranza għall-corticosteroids jew meta titkompla l-kura bil-corticosteroids m'hijiex adattata (ara sezzjoni 4.